(Q51911689)

English

Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration.

scientific article published in February 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17034006

Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17034006

0 references

1 reference

based on heuristic

inferred from title

Parkinson's disease

1 reference

based on heuristic

inferred from title

author name string

Jose M Rabey

1

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17034006

Tatiana Prokhorov

2

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17034006

Ala Miniovitz

3

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17034006

Eugenia Dobronevsky

4

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17034006

Colin Klein

5

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17034006

language of work or name

0 references

publication date

1 February 2007

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17034006

Movement Disorders

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17034006

22

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17034006

3

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17034006

313-318

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17034006

Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.21116

21 January 2018

Quetiapine for l-dopa-induced psychosis in PD.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.21116

21 January 2018

Quetiapine for l-dopa-induced psychosis in PD

1 reference

https://api.crossref.org/works/10.1002%2FMDS.21116

21 January 2018

Risk factors for nursing home placement in advanced Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.21116

21 January 2018

Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.21116

21 January 2018

Identifiers

10.1002/MDS.21116

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17034006

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17034006

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51911689&oldid=1236900032"